Table I.
Serum levels of PSA, FGF1 and FGFR2 in patients with PCa.
| Group | n | PSA (ng/l) | FGF1 (pg/ml) | FGFR2 (pg/ml) |
|---|---|---|---|---|
| Control | 26 | 1.03±0.62 | 203.72±25.27 | 64.14±11.11 |
| PCa | 33 | 21.65±12.18 | 304.02±45.79 | 88.26±10.09 |
| Gleason score | ||||
| 4–6 | 12 | 13.42±5.69 | 304.93±57.13 | 88.60±12.92 |
| 7 | 9 | 20.87±12.86 | 318.36±29.26 | 88.40±8.19 |
| 8–10 | 12 | 30.46±10.97 | 292.36±43.54 | 87.03±9.24 |
| Clinical stage | ||||
| T1 | 4 | 8.09±1.94 | 314.42±60.76 | 89.125±12.17 |
| T2 | 6 | 15.15±5.51 | 304.03±54.08 | 88.65±14.13 |
| T3 | 15 | 20.34±10.35 | 308.78±43.85 | 88.19±8.56 |
| T4 | 8 | 35.76±8.27 | 289.89±41.58 | 86.49±10.86 |
PSA, prostate-specific antigen; FGF1, fibroblast growth factor 1; FGFR2, fibroblast growth factor receptor 2; PCa, prostate cancer.